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Introduction: Recognizing fungal keratitis based on the clinical presentation
is challenging. Topical therapy may be initiated with antibacterial agents and
corticosteroids, thus delaying the fungal diagnosis. As a consequence, the fungal
infection may progress ultimately leading to more severe infection and blindness. We
noticed an increase of fungal keratitis cases in the Netherlands, especially caused by
Fusarium species, which prompted us to conduct a retrospective cohort study, aiming
to describe the epidemiology, clinical management, and outcome.
Materials and Methods: As fungi are commonly sent to the Dutch mycology reference
laboratory for identification and in vitro susceptibility testing, the fungal culture collection
was searched for Fusarium isolates from corneal scrapings, corneal swabs, and from
contact lens (CL) fluid, between 2005 and 2016. All Fusarium isolates had been identified
up to species level through sequencing of the ITS1-5.8S-ITS2 region of the rDNA and
TEF1 gene. Antifungal susceptibility testing was performed according to the EUCAST
microbroth dilution reference method. Antifungal agents tested included amphotericin B,
voriconazole, and natamycin. In addition, susceptibility to the antisepticum chlorhexidine
was tested. Ophthalmologists were approached to provide demographic and clinical
data of patients identified through a positive culture.
Results: Between 2005 and 2016, 89 cases of Fusarium keratitis from 16 different
hospitals were identified. The number of cases of Fusarium keratitis showed a significant
increase over time (R2 = 0.9199), with one case in the first 5 years (2005–2009) and
multiple cases from 2010 and onwards. The male to female ratio was 1:3 (p = 0.014).
Voriconazole was the most frequently used antifungal agent, but treatment strategies
differed greatly between cases including five patients that were treated with chlorhexidine
0.02%monotherapy. Keratitis management was not successful in 27 (30%) patients, with
20 (22%) patients requiring corneal transplantation and seven (8%) requiring enucleation
or evisceration. The mean visual acuity (VA) was moderately impaired with a logMAR
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of 0.8 (95% CI 0.6–1, Snellen equivalent 0.16) at the time of Fusarium culture. Final
average VA was within the range of normal vision [logMAR 0.2 (95% CI 0.1–0.3), Snellen
equivalent 0.63]. CL wear was reported in 92.9% of patients with Fusarium keratitis.
The time between start of symptoms and diagnosis of fungal keratitis was significantly
longer in patients with poor outcome as opposed to those with (partially) restored vision;
22 vs. 15 days, respectively (mean, p = 0.024). Enucleation/evisceration occurred in
patients with delayed fungal diagnosis of more than 14 days after initial presentation of
symptoms. The most frequently isolated species was F. oxysporum (24.7%) followed by
F. solani sensu stricto (18%) and F. petroliphilum (9%). The lowest MICs were obtained
with amphotericin B followed by natamycin, voriconazole, and chlorhexidine.
Conclusion: Although Fusarium keratitis remains a rare complication of CL wear,
we found a significant increase of cases in the Netherlands. The course of infection
may be severe and fungal diagnosis was often delayed. Antifungal treatment strategies
varied widely and the treatment failure rate was high, requiring transplantation or even
enucleation. Our study underscores the need for systematic surveillance of fungal keratitis
and a consensus management protocol.
Keywords: fungal keratitis, Fusarium, susceptibility, identification, contact lenses, visual outcome, chlorhexidine
INTRODUCTION
Fungal keratitis is a common eye infection in tropical and
subtropical areas of the world, but is rarely observed in temperate
climates. The clinical diagnosis of fungal keratitis is difficult, and
antifungal therapy may be delayed due to primary therapy with
antibacterial agents, antiviral agents and topical corticosteroids.
As a consequence, the infectionmay progress in the cornea which
ultimately may lead to more severe infection and monocular
blindness. Although many fungi have been reported to cause
fungal keratitis, Fusarium species are the most frequent cause
(Gopinathan et al., 2002; Iyer et al., 2006). Fusarium species are
fast-growing hyalohyphomycetes and are ubiquitous organisms
that are present in soil, water, and plants. As filamentous
fungi cannot penetrate intact cornea, the most common route
of infection is through (micro) trauma or disruptive ocular
surface disease. Several epidemiological studies indicate that the
frequency of Fusarium keratitis may be increasing (Cheng et al.,
1999; Stapleton et al., 2008, 2012; Jurkunas et al., 2009; Nielsen
et al., 2015; Walther et al., 2017). Based on a perceived increase
of ocular Fusarium isolates sent to the Dutch mycology reference
laboratory (Center of Expertise inMycology Radboudumc/CWZ,
Nijmegen, the Netherlands) for identification and in vitro
susceptibility testing, a national survey was initiated. As there was
no surveillance or registry of keratitis cases in the Netherlands,
we traced possible keratitis cases using the Fusarium cultures that
had been sent to the mycology reference laboratory. Through
this survey we aimed to describe the epidemiology of Fusarium
keratitis, as well as the clinical implications and management.
MATERIALS AND METHODS
The culture collection of the Dutch mycology reference
laboratory was searched for Fusarium isolates from corneal
scrapings, corneal swabs and from contact lens (CL) fluid, which
had been sent for identification and in vitro susceptibility testing
between the beginning of 2005 and the end of 2016. Isolates were
identified to the genus level using microscopic and macroscopic
characteristics. Fusarium isolates from patients with confirmed
fungal keratitis were identified to the species level through
sequencing of the ITS1-5.8S-ITS2 region of the rDNA and TEF1
gene, as described previously (Salah et al., 2015).
In vitro antifungal susceptibility testing (AFST) was
performed according to the EUCAST microdilution reference
method (Roiquez Tudela et al., 2008; Arendrup et al., 2015). The
antifungal agents tested included amphotericin B (Bristol Myers
Squibb), voriconazole (Pfizer), and natamycin (Sigma-Aldrich).
In addition, the activity of the antiseptic agent chlorhexidine
(Pharmaline) was tested.
Through the clinical microbiology laboratories that had
sent Fusarium isolates to the mycology reference laboratory,
ophthalmologists were identified who had treated the keratitis
infection. The ophthalmologists were asked to complete an
online questionnaire regarding the keratitis case including
demographic data (year of birth and gender) and clinical
data including usage and type of CLs, visual acuity (VA)
at diagnosis and after treatment, time between start of
complaints and diagnosis of fungal keratitis and which
kind of treatment was used including corticosteroid use.
Antifungal treatment failure was defined as the need of
corneal transplantation or enucleation/evisceration. Visual
acuity was classified according to the ICD-11/“WHO
classification of vision impairment” (ICD-11 for Mortality
Morbidity Statistics, 2019). The categories of distance visual
impairment are; mild (Snellen VA worse than 0.5), moderate
(Snellen VA worse than 0.3), severe (Snellen VA worse than
0.1), and blindness (Snellen VA worse than 0.05 or only
light perception).
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The statistical analysis was performed with IBM SPSS
Statistics 25. To estimate the association of CL wear with fungal
keratitis the number of CL wearers in the Dutch community in
2012 served as control group (Bruggink, 2013). The collection of
samples and clinical data from the patients were collected and
processed in agreement with the Declaration of Helsinki.
RESULTS
Epidemiology and Patient Demographics
On the basis of collected isolates, 89 Fusarium keratitis cases were
identified from 16 different hospitals in the Netherlands over a
period of 12 years. Only one case was identified in the first 5
years (2005–2009), while all other cases were found from 2010
onwards (Figure 1). The number of cases of Fusarium keratitis
showed a significant increasing trend over time (R2 = 0.9199).
The population in the Netherlands was ∼16.6 million in this
period, which leads to a mean incidence of 0.45 (range 0–1.5) per
million per year. The male (n = 32) to female (n = 57) ratio was
1:3 (p= 0.014) with a mean age of 42 years (range 13–85). Other
clinical characteristics are shown in Table 1.
Treatment Strategies
In 66 cases the treatment was known at the time of diagnosis
of fungal keratitis (one of which received no antimicrobial
therapy), and treatment strategies varied greatly. All 65 patients
received topically administered antimicrobial agents (Table 1). In
39 (59.1%) patients only topical antibiotics were used, while 25
(37.9%) patients received a combination of antibiotics, antivirals
and/or antifungals. One patient was already receiving antifungal
therapy (intraocular injected amphotericin B) when the diagnosis
Fusarium keratitis was made. Of 68 cases the treatment strategy
after a fungus was cultured was known (see Table 1 for more
details). Therapy was changed to amphotericin B in eight patients
(11.8%), to voriconazole in 21 patients (30.9%), and in one
case to natamycin, which is not commercially available in the
Netherlands. Eight patients continued with antibiotics alone.
In 21 patients (30.9%) a combination of antibiotics, antivirals
and/or antifungals was administered. Of note, five patients were
treated with chlorhexidine 0.02% monotherapy after Fusarium
was cultured.
Treatment Outcome
Keratitis management was not successful in 27 (30%) patients,
with 20 (22%) patients needing corneal transplantation. Three
eyes, which already underwent a cornea transplant to debulk
the fungal load, were eventually enucleated and evisceration was
performed in four additional cases (8%). The mean VA was
moderately impaired at the time of Fusarium keratitis diagnosis
with a logMAR of 0.8 (95% CI 0.6–1, Snellen equivalent 0.16).
The final VA outcome (excluding the enucleated/eviscerated
patients) measured 0.2 logMAR on average (95% CI 0.1–0.3,
Snellen equivalent 0.63), which is compatible with normal
everyday activities (suboptimal but within the range of normal
vision). Regarding the VA there was no significant difference
between a severe or mild to moderate outcome regarding
corticosteroid use before diagnosis (p = 0.08, Fisher’s Exact
Test). Complete response was achieved with chlorhexidine
monotherapy in four of five patients, whereas one required a
cornea transplantation.
FIGURE 1 | Number of Fusarium keratitis cases in The Netherlands during the period 2005−2016.
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TABLE 1 | Clinical characteristics and outcome in Dutch patients with Fusarium
keratitis.
No. (% or range)
Total no. of cases 89
Age (years) 42 (13–85)









Visual acuity at diagnosis†
logMAR 0.8 (−0.10 to 3)
Snellen 0.16 (0.001–1.25)




Cornea transplantation 20 (22.5%)
Enucleation/evisceration 7 (7.9%)
Healed infiltrate 62 (69.6%)










Antimicrobial treatment after diagnosis
Amphotericin B (T) 7 (7.9%)
Amphotericin B (T+S) 1 (1.1%)
Voriconazole (T) 14 (15.7%)
Voriconazole (T+S) 6 (6.7%)
Voriconazole (T+S+I) 1 (1.1%)
Natamycin (T) 1 (1.1%)





*Combinations of antibiotics, antifungals, antivirals, and/or antiseptics.




Only five patients recalled a trauma to the affected eye; due
to penetration by biological material or a corpus alienum. In
70 patients information regarding the use of CLs was available,
and 65 (93%) of these wore a contact lens in the affected eye;
primarily soft CLs (94%) and only a few rigid gas permeable CLs
(6%). The time between start of symptoms and the diagnosis
of fungal keratitis was significantly longer in the group with a
poor outcome (VA worse than 0.1 logMAR, Snellen equivalent
0.8) as opposed to the group with (partially) restored vision;
respectively, 22 vs. 15 days (p = 0.024, calculated by logistic
regression and corrected for missing data). Corticosteroids were
frequently used before the diagnosis of fungal keratitis was made.
In this cohort 18% of the cases were given topical corticosteroids
alongside antimicrobial agents.
Strain Identification and Susceptibility
Profile
Molecular species identification, showed that F. oxysporum (n
= 22, 24.7%) was the most frequently isolated species followed
by F. solani sensu stricto (n = 16, 18%) and F. petroliphilum
(n = 8, 9%) (Table 2). Based on the assignment of the isolates
to the according species complex, as described by Salah (Salah
et al., 2015), the most frequent encountered complexes were
F. solani species complex (FSSC, n = 32, 36%), followed by
F. oxysporum species complex (FOSC, n = 22, 24.7%) and F.
fujikuroi species complex (FFSC, n = 15, 16.9%). Overall, 10
isolates were not molecularly identified and one isolate could
not be speciated and is believed to represent a new Fusarium
species. A relationship between Fusarium species and disease
severity of treatment outcome could not be established. In vitro
susceptibility testing indicated that amphotericin B was the most
active antifungal agent followed by natamycin, voriconazole, and
chlorhexidine (Table 2).
DISCUSSION
Our retrospective study of Fusarium cultures obtained from
cornea samples and subsequent case finding indicated a
significant increase of Fusarium keratitis cases in the Netherlands
since 2010. We found an estimated mean incidence of 0.45 cases
per million per year, which increased from sporadic cases in
2005 to 1.5 cases per million in 2015. We acknowledge that
our estimate is prone to bias as we lack a reliable denominator
and practices of sending fungal isolates to the mycology
reference laboratorymight have changed over time. However, our
observation is in keeping with a general increase of keratitis cases
and reports of increasing fungal keratitis cases in other countries
such as the USA, Denmark and Germany (Jurkunas et al., 2009;
Nielsen et al., 2015; Walther et al., 2017). Furthermore, one
previous study indicated that the incidence of fungal keratitis was
very low before 2010 in the Netherlands (Cheng et al., 1999). In
1996, 92 cases of microbial keratitis were identified through a
3-month national survey in the Netherlands, with no cases due
to Fusarium species (Cheng et al., 1999). A second single center
study identified 109 keratitis cases over a 5-year period (2005–
2009) that required hospitalization (Hoddenbach et al., 2014).
Two cases of fungal keratitis were identified (1.8%), which may
indicate that the course of infection is relatively severe in fungal
infection compared with bacterial or viral infection.
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TABLE 2 | Molecularly identified fusarial keratitis isolates and their susceptibility profile including chlorhexidine (only identified strains are depicted, n = 78 and MICs
presented as commonly used concentrations).
MIC* % [mode (range)] MIC* mg/L [mode (range)]
Fusarium species complex and species (n) CHX CHX AMB VCZ NAT POS
F. solani species complex—FSSC (32) 0.003 (0.0015–0.006) 16 (8–32) 2 (0.5–16) 8 (4–16) 8 (4–16) 16
F. solani (16) 0.006 (0.0015–0.006) 32 (8–32) 2 (1–16) 8 (4–16) 8 (4–16) 16
F. petroliphilum (8) 0.0015 (0.0015–0.006) 8 (8–32) 2 (0.5–4) 8 (4–16) 4 (4–8) 16
F. keratinoplasticum (7) 0.003 (0.0015–0.006) 16 (8–32) 4 (2–4) 4 (4–16) 4 (4–8) 16
F. falciforme (1) 0.006 32 2 16 8 16
F. oxysporum species complex—FOSC (22) 0.0015 (0.0002–0.013) 8 (1–64) 2 (0.25–16) 4 (2–16) 8 (4–8) 16
F. oxysporum (22) 0.0015 (0.0002–0.013) 8 (1–64) 2 (0.25–16) 4 (2–16) 8 (4–16) 16
F. fujikuroi species complex—FFSC (15) (0.0008–0.013)# (4–64)# 2 (1–4) 4 (1–8) 8 (2–8) 16 (0.25–16)
F. proliferatum (7) 0.0008(0.0008–0.013) 4 (4–64) 1 (1–4) 4 (2–8) 8 (4–8) (2–16)#
F. verticillioides (2) (0.0008–0.003)# (4–16)# (1–2)# (1–2)# (2–8)# (0.25–0.5)#
F. lactis (3) 0.0015 (0.0015–0.003) 8 (8–16) (0.5–4)# (2–8)# 8 16 (2–16)
F. sacchari (1) 0.0015 8 2 1 8 0.25
F. ramigenum (1) 0.003 16 4 1 4 1
F. musae (1) 0.003 16 2 4 8 1
F. dimerum species complex—FDSC (7) 0.0015 (0.0015–0.003) 8 (8–16) 2 (0.5–2) 8 4 (4–16) 16
F. dimerum (7) 0.0015 (0.0015–0.003) 8 (8–16) 2 (0.5–2) 8 4 (4–16) 16
F. equiseti-incarnatum species complex—FIESC (1) † † 1 8 † 16
F. equiseti (1) † † 1 8 † 16
Ambrosia Fusarium complex—AFC (1) 0.006 32 2 16 8 16
F.ambrosium (1) 0.006 32 2 16 8 16
*MIC, minimal inhibitory concentration; AMB, amphotericin B; VCZ, voriconazole; POS, posaconazole; NAT, natamycin; CHX, chlorhexidine.
#Mode not calculable (even numbers).
†
Susceptibility testing was not performed.
Our survey indeed indicated that Fusarium keratitis is a severe
infection with almost one-third of patients failing initial therapy.
There are several factors that contribute to a poor outcome
including delayed diagnosis. We could not assess if delay was
due to patients delay, physicians delay or a combination of both.
However, all patients who required evisceration or enucleation
were diagnosed more than 14 days after onset of symptoms,
underscoring that early diagnosis (and treatment) is critical for
a favorable outcome. Early diagnosis could involve adding fungal
culture media if cornea scrapings are sent for culture, or adding
fungal targets to molecular testing. Another factor is the use of
corticosteroids, which is a known risk factor for invasive fungal
diseases and mycotic keratitis (Thomas and Kaliamurthy, 2013).
In our cohort 18% of the patients received topical corticosteroids
before the diagnosis of fungal keratitis. Unfortunately, the data
set did not contain the used dosage of corticosteroids which
presents a limitation of our study. We could, however, not
demonstrate a significant difference between mild to moderate
and severe outcome and the use of corticosteroids.
Given the wide variety of treatment strategies, our survey
indicated an apparent uncertainty how best to treat Fusarium
keratitis. Although the national guideline recommends topical
amphotericin B (Kullberg et al., 2017), most regimens used
in our cohort included voriconazole. The ocular toxicity and
symptoms associated with local amphotericin B in combination
with the well-documented ocular penetration of voriconazole
1% eye drops may have played a role in this transition. One
problem is a lack of convincing studies to support evidence-
based treatment choices, as current clinical trials are generally
underpowered and of variable quality (FlorCruz and Evans,
2015). Furthermore, the available antifungal agents including
amphotericin B 0.15% and voriconazole 1% are not commercially
available as ophthalmic drops in our country and are made-to-
order by hospital pharmacists.
Rational treatment choices are also hampered by the lack of
correlation between MIC and drug efficacy. The most frequently
isolated Fusarium species complexes (FSSC, FOSC and FFSC)
are generally multidrug resistant in vitro and any activity is at
best fungistatic (Oliveira dos Santos et al., 2019). The use of
MICs to guide treatment choices is limited due to the fact that
through topical therapy the fungus is exposed to very high drug
concentrations and thus may respond despite a high in vitro
MIC. There is increasing evidence that chlorhexidine may be
effective for the treatment of Fusarium keratitis, supported by
both clinical trials and in vitro studies (Rahman et al., 1997, 1998).
We recently showed that chlorhexidine exhibited fungicidal
activity against a broad range of filamentous fungi including
Fusarium species, at concentrations that could be readily
achieved clinically (Oliveira dos Santos et al., 2019). The activity
of chlorhexidine against Acanthamoeba and bacteria makes it a
very attractive agent for local treatment of keratitis. However,
not much is known about its penetration into the cornea and
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aqueous humor. Theoretically, chlorhexidine digluconate should
penetrate the cornea better than the polyenes which have a higher
molecular weight.
The main risk factor for Fusarium keratitis was the use of
soft CLs for extended wear. In our cohort with known reported
use or non-use of CLs, 93% (73% of the complete cohort)
of the cases wore CLs, this is much higher than the normal
coverage of CL use in the normal Dutch population. In 2012
the prevalence of CL wearers in the Dutch population was
estimated to be 12% (Bruggink, 2013). In the years prior to
and after 2012 the prevalence did not fluctuate significantly.
The odds of contracting fungal keratitis amongst CL wearers
is therefore 20 times higher than in non-CL wearers (OR
19.8, 95% CI: 9.39–41.87). Stapleton et al., also found a high
incidence of microbial keratitis in wearers of different CL types
in comparison to the community, but the study did not report
fungal keratitis cases (Stapleton et al., 2008, 2012). We can only
speculate on the cause of the observed increasing frequency
of Fusarium keratitis. Possibilities include (1) non-compliance
to the approved maximum wear recommendation of extended
wear CLs, (2) cleaning CLs with tap water or saliva, and (3)
reduced fungal activity of CL solutions. Prevention of infection
through education on proper use of CLs and adherence to
recommended cleaning and disinfection protocols remains an
important goal.
Although Fusarium keratitis remains a rare complication of
CL wear, our study indicates that the course of infection may
be severe, diagnosis is often delayed and treatment options are
limited. Systematic surveillance is needed to confirm our findings
and monitor trends in prevalence. Furthermore, a consensus
treatment strategy is warranted to optimize and standardize
antifungal therapy. The antiseptic chlorhexidine might be an
attractive treatment option given its broad antimicrobial activity
but further studies would be required to confirm its efficacy
and safety.
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